9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Estimated reading time: 1 min

Condition: Solid Tumor

Estimated Enrollment: 135

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Phase 1a: To assess safety and tolerability of ASTX295 including determination of maximum tolerated dose (MTD), and/or recommended dose for expansion (RDE) to Phase 1b.,  Phase 1b: To determine the recommended Phase 2 dose (RP2D) and regimen of ASTX295 to proceed to Phase 2.,  Phase 1: To evaluate the preliminary clinical activity of ASTX295 as assessed by disease control rate (DCR)., Phase 1: To evaluate the preliminary clinical activity as assessed by objective response rate (ORR) of ASTX295.

Interventions: ASTX295,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: April 22, 2023

Completion Date: May 27, 2023

Last  Posted Date: August 1, 2019

Location: The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT03975387

Was this article helpful?
Dislike 0